 Subjects will be assessed at week -4 run-in wash-out, 0ab screening phase, 1, 5, 9, 13, and 20. Descriptive statistics will be used to summarize continuous and categorical variables. Mean change of Lpa levels will be compared between treatment and placebo group. Subjects will be grouped according to treatment randomised intention-to-treat, ITT population. For missing data, the last observation will be carried forward LOCF. Comparisons between groups will be performed using analysis of covariance ANCOVA with treatment as a factor, adjusting for baseline Lpa levels and other potential confounders. 